{"id":"https://openalex.org/W2145251502","doi":"https://doi.org/10.1158/1535-7163.mct-09-0568","title":"The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activityin vivo","display_name":"The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activityin vivo","publication_year":2009,"publication_date":"2009-12-01","ids":{"openalex":"https://openalex.org/W2145251502","doi":"https://doi.org/10.1158/1535-7163.mct-09-0568","mag":"2145251502","pmid":"https://pubmed.ncbi.nlm.nih.gov/19952119"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-09-0568","doi":"https://doi.org/10.1158/1535-7163.mct-09-0568","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-0568","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074128964","display_name":"Mark Douglas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Douglas","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts","Infinity Pharmaceuticals, 780 Memorial Drive, Cambridge, MA 02139, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]},{"raw_affiliation_string":"Infinity Pharmaceuticals, 780 Memorial Drive, Cambridge, MA 02139, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028296814","display_name":"Alice R. Lim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alice R. Lim","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103028267","display_name":"James R. Porter","orcid":"https://orcid.org/0000-0002-6633-9475","observed_orcids":["https://orcid.org/0000-0002-6633-9475"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James R. Porter","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046123085","display_name":"Kip A. West","orcid":"https://orcid.org/0000-0002-3891-0830","observed_orcids":["https://orcid.org/0000-0002-3891-0830"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kip West","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061333328","display_name":"Melissa M. Pink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa M. Pink","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108501532","display_name":"Jie Ge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jie Ge","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054650617","display_name":"Andrew A. Wylie","orcid":"https://orcid.org/0009-0000-2694-231X","observed_orcids":["https://orcid.org/0009-0000-2694-231X"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew A. Wylie","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076918767","display_name":"Thomas T. Tibbits","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas T. Tibbits","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054953474","display_name":"Kurtis Biggs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kurtis Biggs","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011553566","display_name":"Michael S. Curtis","orcid":"https://orcid.org/0000-0003-2520-8097","observed_orcids":["https://orcid.org/0000-0003-2520-8097"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Curtis","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026760473","display_name":"Vito J. Palombella","orcid":"https://orcid.org/0009-0004-2939-7053","observed_orcids":["https://orcid.org/0009-0004-2939-7053"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vito J. Palombella","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102789608","display_name":"Julian Adams","orcid":"https://orcid.org/0000-0002-9610-6293","observed_orcids":["https://orcid.org/0000-0002-9610-6293"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julian Adams","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032421989","display_name":"Christian Fritz","orcid":"https://orcid.org/0000-0002-6508-1011","observed_orcids":["https://orcid.org/0000-0002-6508-1011"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christian C. Fritz","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048284232","display_name":"Emmanuel Normant","orcid":"https://orcid.org/0000-0002-0570-5072","observed_orcids":["https://orcid.org/0000-0002-0570-5072"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emmanuel Normant","raw_affiliation_strings":["Infinity Pharmaceuticals, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210108457"],"apc_list":null,"apc_paid":null,"fwci":1.2001,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":{"value":0.75154562,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"8","issue":"12","first_page":"3369","last_page":"3378"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10934","display_name":"Heat shock proteins research","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10934","display_name":"Heat shock proteins research","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.007000000216066837,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11332","display_name":"Genomics, phytochemicals, and oxidative stress","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipi-504","display_name":"IPI-504","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hsp90","display_name":"HSP90","score":0.7020000219345093},{"id":"https://openalex.org/keywords/nqo1","display_name":"NQO1","score":0.8550000190734863},{"id":"https://openalex.org/keywords/nad-p-h-quinone-oxidoreductase-1","display_name":"NAD(P)H:quinone oxidoreductase 1","score":0.9490000009536743},{"id":"https://openalex.org/keywords/17-aag","display_name":"17-AAG","score":0.7870000004768372},{"id":"https://openalex.org/keywords/ansamycins","display_name":"ansamycins","score":0.6349999904632568},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.847000002861023},{"id":"https://openalex.org/keywords/cancer-cell-lines","display_name":"cancer cell lines","score":0.796999990940094},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.7940000295639038},{"id":"https://openalex.org/keywords/hsp90-client-proteins","display_name":"Hsp90 client proteins","score":0.7070000171661377},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6690000295639038}],"concepts":[{"id":"https://openalex.org/C2777550763","wikidata":"https://www.wikidata.org/wiki/Q419164","display_name":"Hydroquinone","level":2,"score":0.7236839532852173},{"id":"https://openalex.org/C2780297055","wikidata":"https://www.wikidata.org/wiki/Q904475","display_name":"Geldanamycin","level":5,"score":0.7099300622940063},{"id":"https://openalex.org/C75520062","wikidata":"https://www.wikidata.org/wiki/Q15321392","display_name":"NAD+ kinase","level":3,"score":0.6447145938873291},{"id":"https://openalex.org/C2780643102","wikidata":"https://www.wikidata.org/wiki/Q412382","display_name":"Quinone","level":2,"score":0.5715344548225403},{"id":"https://openalex.org/C79879829","wikidata":"https://www.wikidata.org/wiki/Q5571762","display_name":"Intracellular","level":2,"score":0.5652588605880737},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.5646743178367615},{"id":"https://openalex.org/C2775932338","wikidata":"https://www.wikidata.org/wiki/Q24772687","display_name":"Hsp90","level":4,"score":0.5205498933792114},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.5060119032859802},{"id":"https://openalex.org/C205260736","wikidata":"https://www.wikidata.org/wiki/Q418939","display_name":"Heat shock protein","level":3,"score":0.48696598410606384},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.43317604064941406},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.43182775378227234},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4313240647315979},{"id":"https://openalex.org/C2779268744","wikidata":"https://www.wikidata.org/wiki/Q407479","display_name":"Oxidoreductase","level":3,"score":0.4228162467479706},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4151343107223511},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.37266993522644043},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.05357101559638977},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006873","descriptor_name":"Hydroquinones","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015151","descriptor_name":"Immunoblotting","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016227","descriptor_name":"Benzoquinones","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016227","descriptor_name":"Benzoquinones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016660","descriptor_name":"NAD(P)H Dehydrogenase (Quinone)","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016660","descriptor_name":"NAD(P)H Dehydrogenase (Quinone)","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018841","descriptor_name":"HSP90 Heat-Shock Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018841","descriptor_name":"HSP90 Heat-Shock Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019073","descriptor_name":"HT29 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020014","descriptor_name":"K562 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045325","descriptor_name":"HCT116 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047029","descriptor_name":"Lactams, Macrocyclic","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D047029","descriptor_name":"Lactams, Macrocyclic","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047368","descriptor_name":"Tumor Burden","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-09-0568","doi":"https://doi.org/10.1158/1535-7163.mct-09-0568","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-0568","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:19952119","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19952119","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":46,"referenced_works":["https://openalex.org/W560362396","https://openalex.org/W1925723678","https://openalex.org/W1980813154","https://openalex.org/W1988692190","https://openalex.org/W1989024725","https://openalex.org/W1989814127","https://openalex.org/W2000929246","https://openalex.org/W2007106751","https://openalex.org/W2011885790","https://openalex.org/W2017250052","https://openalex.org/W2017434303","https://openalex.org/W2018298451","https://openalex.org/W2018462246","https://openalex.org/W2019431066","https://openalex.org/W2025396651","https://openalex.org/W2031284766","https://openalex.org/W2053356355","https://openalex.org/W2058536932","https://openalex.org/W2064465768","https://openalex.org/W2064842635","https://openalex.org/W2078558213","https://openalex.org/W2079434650","https://openalex.org/W2084973261","https://openalex.org/W2088942787","https://openalex.org/W2089290845","https://openalex.org/W2097186003","https://openalex.org/W2099546104","https://openalex.org/W2100611890","https://openalex.org/W2109635468","https://openalex.org/W2117807601","https://openalex.org/W2126653080","https://openalex.org/W2135166855","https://openalex.org/W2144332765","https://openalex.org/W2158780525","https://openalex.org/W2162107265","https://openalex.org/W2166999544","https://openalex.org/W2167852241","https://openalex.org/W2170190793","https://openalex.org/W2254630361","https://openalex.org/W2257175342","https://openalex.org/W2257690327","https://openalex.org/W2268361684","https://openalex.org/W3022312776","https://openalex.org/W3080873770","https://openalex.org/W4248379810","https://openalex.org/W6675065306"],"related_works":["https://openalex.org/W2117807601","https://openalex.org/W2053635967","https://openalex.org/W7095171799","https://openalex.org/W2566530718","https://openalex.org/W2548610444","https://openalex.org/W2917813256","https://openalex.org/W3166214039","https://openalex.org/W1965787931","https://openalex.org/W2322255690","https://openalex.org/W2125221090"],"abstract_inverted_index":{"IPI-504,":[0,176],"a":[1,12,47,94,142,226],"water-soluble":[2],"ansamycin":[3],"analogue":[4],"currently":[5],"being":[6],"investigated":[7],"in":[8,46,125,141,204,216,231,244],"clinical":[9],"trials,":[10],"is":[11,164,224],"potent":[13],"inhibitor":[14],"of":[15,25,32,42,88,102,123,144,157,162,170,184,190,202,207,228],"the":[16,30,39,56,72,78,86,99,131,153,168,182,186,199,245],"protein":[17,21],"chaperone":[18],"heat":[19],"shock":[20],"90":[22],"(Hsp90).":[23],"Inhibition":[24],"Hsp90":[26],"by":[27],"IPI-504":[28,43,124,203,215,229,243],"triggers":[29],"degradation":[31],"important":[33,239],"oncogenic":[34],"client":[35],"proteins.":[36],"In":[37],"cells,":[38],"free":[40],"base":[41],"hydroquinone":[44,57,80,103,171],"exists":[45],"dynamic":[48],"redox":[49],"equilibrium":[50],"with":[51,117,137,152],"its":[52],"corresponding":[53],"quinone":[54,105],"(17-AAG);":[55],"form":[58],"binding":[59],"50":[60],"times":[61],"more":[62],"tightly":[63],"to":[64,96,104,112,166,175,214,236,242],"Hsp90.":[65],"It":[66],"has":[67,178],"been":[68],"proposed":[69],"recently":[70],"that":[71,210,221],"NAD(P)H:quinone":[73],"oxidoreductase":[74],"NQO1":[75,114,138,163,222],"can":[76],"produce":[77],"active":[79,188],"and":[81,107,120,147,172],"could":[82,194],"be":[83],"essential":[84],"for":[85,198],"activity":[87,122,156,183,201,223,230],"IPI-504.":[89,158,191],"Here,":[90],"we":[91],"have":[92,108],"devised":[93],"method":[95],"directly":[97],"measure":[98],"intracellular":[100,132],"ratio":[101,119,134],"(HQ/Q)":[106],"applied":[109],"this":[110],"measurement":[111],"correlate":[113],"enzyme":[115],"abundance":[116],"HQ/Q":[118,133],"cellular":[121],"30":[126],"cancer":[127],"cell":[128,145,173,208],"lines.":[129],"Interestingly,":[130],"was":[135,149],"correlated":[136,151],"levels":[139],"only":[140],"subset":[143],"lines":[146,209],"overall":[148],"poorly":[150],"growth":[154],"inhibitory":[155],"Although":[159],"artificial":[160],"overexpression":[161],"able":[165],"increase":[167],"level":[169],"sensitivity":[174],"it":[177],"little":[179],"effect":[180],"on":[181],"17-amino-17-demethoxy-geldanamycin,":[185],"major":[187],"metabolite":[189],"This":[192],"finding":[193],"provide":[195],"an":[196,238],"explanation":[197],"biological":[200],"xenograft":[205],"models":[206],"are":[211],"not":[212,225],"sensitive":[213],"vitro.":[217],"Our":[218],"results":[219],"suggest":[220],"determinant":[227],"vivo":[232],"and,":[233],"therefore,":[234],"unlikely":[235],"become":[237],"resistance":[240],"mechanism":[241],"clinic.":[246]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}